S6k1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer

American Journal of Translational Research

Volumn 6, Issue 4, 2014, Pages 361-376

  Khotskaya, Yekaterina B ^a   Goverdhan, Aarthi ^a,b   Shen, Jia ^a,b   Ponz Sarvise, Mariano ^a   Chang, Shih Shin ^a,b   Hsu, Ming Chuan ^a   Wei, Yongkun ^a   Xia, Weiya ^a   Yu, Dihua ^a,b   Hung, Mien Chie ^a,b,c,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Bone; Metastasis; S6; S6k1; TNBC

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 4708671; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CELL ADHESION ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING;

EID: 84904568650     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Lin Y, Yin W, Yan T, Zhou L, Di G, Wu J, Shen Z, Shao Z and Lu J. Site-specifc relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 2009; 9: 342.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC, Ouyang F and Hou MF. Distant metastasis in triple-negative breast cancer. Neoplasma 2013; 60: 290-294.
4. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hor-tobagyi GN and Pusztai L. Response to neoad-juvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
5. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, Dewitty RL Jr and Frederick WA. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surg 2008; 195: 153-158.
6. Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP and Sorensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer 2011; 11: 29.
7. Yong M, Jenson AO, Jacobsen JB, Norgaard M, Fryzek JP and Sorensen HT. The Incidence of Bone Metastases and Skeletal-Related Events in Breast Cancer Patients: A Population-Based Cohort Study in Denmark (1999-2007). Cancer Res 2009; 69: 608S-609S.
8. Berman AT, Thukral AD, Hwang WT, Solin LJ and Vapiwala N. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer 2013; 13: 88-94.
9. Irvin W Jr, Muss HB and Mayer DK. Symptom management in metastatic breast cancer. Oncologist 2011; 16: 1203-1214.
10. Rosa Mendoza ES, Moreno E and Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol 2013; 139: 645-652.
11. Koo JS, Jung W and Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010; 96: 424-432.
12. Goldstein RH, Weinberg RA and Rosenblatt M. Of mice and (wo)men: mouse models of breast cancer metastasis to bone. J Bone Miner Res 2010; 25: 431-436.
13. Yoneda T, Michigami T, Yi B, Williams PJ, Nie-wolna M and Hiraga T. Actions of bisphospho-nate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 2979-2988.
14. Nola S, Sin S, Bonin F, Lidereau R and Driouch K. A methodological approach to unravel or-gan-specifc breast cancer metastasis. J Mammary Gland Biol Neoplasia 2012; 17: 135-145.
15. Kretschmann KL and Welm AL. Mouse models of breast cancer metastasis to bone. Cancer Metastasis Rev 2012; 31: 579-583.
16. Welch DR, Harms JF, Mastro AM, Gay CV and Donahue HJ. Breast cancer metastasis to bone: evolving models and research challenges. J Musculoskelet Neuronal Interact 2003; 3: 30-38.
17. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005; 102: 13909-13914.
18. Kang Y, Siegel PM, Shu W, Drobnjak M, Ka-konen SM, Cordon-Cardo C, Guise TA and Mas-sague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
19. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R and Massague J. Distinct organ-specifc metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
20. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93-102.
21. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486-1495.
22. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Fei-genbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K and Steeg PS. Her-2 overex-pression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190-4198.
23. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486-1495.
24. Fenton TR and Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 2011; 43: 47-59.
25. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA and Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science 1998; 279: 707-710.
26. Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB and Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphoryla-tion site. J Biol Chem 2002; 277: 20104-20112.
27. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE and Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 1995; 14: 5279-5287.
28. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66: 2028-2037.
29. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN and Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 2010; 9: 1180-1187.
30. Khotskaya YB, Beck BH, Hurst DR, Han Z, Xia W, Hung MC and Welch DR. Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Mol Carcinog 2013; [Epub ahead of print].
31. Debnath J and Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5: 675-688.
32. Debnath J, Muthuswamy SK and Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
33. Price JE, Polyzos A, Zhang RD and Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-721.
34. Zhang RD, Fidler IJ and Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204-215.
35. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
36. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA and Massague J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
37. Zhou H and Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 2011; 12: 30-42.
38. Botteri E, Disalvatore D, Curigliano G, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A and Rotmensz N. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012; 21: 284-288.
39. Steeg PS. Perspective: The right trials. Nature 2012; 485: S58-59.
40. Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M and Steeg PS. Breast Cancer Metastasis: Issues for the Personalization of Its Prevention and Treatment. Am J Pathol 2013;
41. Campbell JP, Merkel AR, Masood-Campbell SK, Elefteriou F and Sterling JA. Models of bone metastasis. J Vis Exp 2012; e4260.
42. Xia TS, Wang GZ, Ding Q, Liu XA, Zhou WB, Zhang YF, Zha XM, Du Q, Ni XJ, Wang J, Miao SY and Wang S. Bone metastasis in a novel breast cancer mouse model containing human breast and human bone. Breast Cancer Res Treat 2012; 132: 471-486.
43. Yang W, Lam P, Kitching R, Kahn HJ, Yee A, Au-bin JE and Seth A. Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther 2007; 6: 1289-1294.
44. Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashry D and Lippman M. A new mouse model for the study of human breast cancer metastasis. PLoS One 2012; 7: e47995.
45. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW and Foekens JA. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24: 2261-2267.
46. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J and Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
47. Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A, Scherneck S and Seitz S. Identifcation of brain- and bone-specifc breast cancer metastasis genes. Cancer Lett 2009; 276: 212-220.
48. Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S and Blackwell KL. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacody-namic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 2011; 17: 6061-6070.
49. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C and Epstein RJ. Phase II study of single-agent bosutinib, a Src/Abl tyrosine ki-nase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012; 23: 610-6 17.
50. Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-Gonzalez S and Holz MK. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene 2012; 31: 5073-5080.
51. Sinclair CS, Rowley M, Naderi A and Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003; 78: 313-322.
52. Segatto I, Berton S, Sonego M, Massarut S, D'Andrea S, Perin T, Fabris L, Armenia J, Ram-pioni G, Lovisa S, Schiappacassi M, Colombatti A, Bristow RG, Vecchione A, Baldassarre G and Belletti B. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol 2013; 5: 428-31.
53. Perez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjold B, Fornander T, Skoog L and Stal O. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat 2011; 128: 713-723.
54. Berven LA, Willard FS and Crouch MF. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296: 183-195.
55. Zhou HY and Wong AS. Activation of p70S6K induces expression of matrix metalloprotein-ase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147: 2557-2566.
56. Liu L, Li F, Cardelli JA, Martin KA, Blenis J and Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 2006; 25: 7029-7040.
57. Gattelli A, Nalvarte I, Boulay A, Roloff TC, Sch-reiber M, Carragher N, Macleod KK, Schleder-er M, Lienhard S, Kenner L, Torres-Arzayus MI and Hynes NE. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med 2013; 5: 1335-1350.
58. Foley J, Nickerson NK, Nam S, Allen KT, Gilm-ore JL, Nephew KP and Riese DJ 2nd. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010; 21: 951-960.
59. Nie F, Yang J, Wen S, An YL, Ding J, Ju SH, Zhao Z, Chen HJ, Peng XG, Wong ST, Zhao H and Teng GJ. Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer 2012; 118: 5198-5209.
60. Lemmon MA and Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
61. Mulligan LM. RET revisited: expanding the on-cogenic portfolio. Nat Rev Cancer 2014; 14: 173-186.
62. Berrada N, Delaloge S and Andre F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol 2010; 21 Sup-pl 7: vii30-35.
63. Wander SA, Zhao DK, Besser AH, Hong F, Wei JQ, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ and Slingerland JM. PI3K/ mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antip-roliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 2013; 138: 369-381.
64. Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hris-tova-Kazmierski M, Shonukan OO, Sledge GW and Miller KD. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs 2009; 27: 565-570.
65. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubis-ta E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W and Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus le-trozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637.
66. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstanti-novic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L and Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as frst-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013; 31: 195-202.
67. Hollebecque A, Houede N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA and Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or evero-limus in patients with solid tumours. Eur J Cancer 2014; 50: 876-884.